Challenges and opportunities for siRNA-based cancer treatment
- 1 February 2017
- journal article
- review article
- Published by Elsevier in Cancer Letters
- Vol. 387, 77-83
Abstract
No abstract availableKeywords
This publication has 84 references indexed in Scilit:
- Targeted drug delivery for cancer therapy: the other side of antibodiesJournal of Hematology & Oncology, 2012
- Harnessing a Physiologic Mechanism for siRNA Delivery With Mimetic Lipoprotein ParticlesMolecular Therapy, 2012
- Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategiesCell Research, 2012
- Is RNAi Dead?Molecular Therapy, 2011
- CLINICAL TRIALS AND TRANSLATIONAL MEDICINE COMMENTARY: Drug Delivery Trends in Clinical Trials and Translational Medicine: Challenges and Opportunities in the Delivery of Nucleic Acid-Based TherapeuticsJournal of Pharmaceutical Sciences, 2011
- Rational Design of Immunostimulatory siRNAsMolecular Therapy, 2010
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature, 2010
- Chemical Modification Patterns Compatible with High Potency Dicer-Substrate Small Interfering RNAsOligonucleotides, 2008
- "Destemming" Cancer Stem CellsJNCI: Journal of the National Cancer Institute, 2007
- Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacyNature Biotechnology, 2004